Idarubicin, Cytarabine and Pravastatin as Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

BACKGROUND: Previous studies suggest that idarubicin/cytarabine(ara-C)/pravastatin (IAP) is an active salvage regimen for patients with AML. We therefore investigated this regimen in patients with newly-diagnosed AML or MDS (≥10% blasts). METHODS: Patients were eligible if the anticipated treatment-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Am J Hematol
Autors principals: Shadman, Mazyar, Mawad, Raya, Dean, Carol, Chen, Tara, Shannon-Dorcy, Kathleen, Sandhu, Vicky, Hendrie, Paul C., Scott, Bart L., Walter, Roland B., Becker, Pamela S., Pagel, John, Estey, Elihu H.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4803479/
https://ncbi.nlm.nih.gov/pubmed/25689471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.23981
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars